Treatment of Hepatocellular Carcinoma with Portal Vein Thrombosis by Sorafenib Combined with Hepatic Arterial Infusion Chemotherapy

Mi Yean Yang*, Soung Won Jeong*, Dong Kyun Kim*, Sang Gyune Kim*, Jae Young Jang*, Young Seok Kim*, Joon Seong Lee*, Boo Sung Kim*, Jung Hoon Kim†, and Yong Jae Kim†

*Institute for Digestive Research, Department of Internal Medicine, †Department of Radiology, Soonchunhyang University Hospital, Seoul, Korea

Treatment with sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced hepatocellular carcinoma. Although the effects of combining sorafenib therapy with other anticancer treatment modalities have not been clarified, combination treatment is strongly expected to be beneficial. We report the case of a 50-year-old man who exhibited a partial response and portal vein thrombosis (PVT) revascularization after sorafenib combined with hepatic arterial infusion chemotherapy (HAIC). He exhibited a decrease in tumor size and PVT after 2 months of sorafenib monotherapy. However, no additional response was seen during the subsequent 2 months. To achieve a better tumor response, we combined HAIC with sorafenib. Daily cisplatin (7 mg/m² on days 1-5) and 5-fluorouracil (170 mg/m² on days 1-5) were infused repeatedly every 4 weeks, and the sorafenib prescription was modified. After four cycles of combined therapy, both the tumor size and PVT were much improved and exhibited partial response. (Gut Liver 2010;4:423-427)

Key Words: Hepatocellular carcinoma; Portal vein thrombosis; Sorafenib; Hepatic arterial infusion chemotherapy

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, behind only lung and stomach cancers.¹ When patients is diagnosed with HCC, only 30% of patients is indicated to potentially curative treatments, such as surgical therapies (resection and liver transplantation) and locoregional treatment (radiofrequency ablation and percutaneous ethanol injection).² For unresectable HCC without vascular invasion or extrahepatic spread, transarterial chemoembolization (TACE) is recommended as the first-line, non-curative therapy.³ However, TACE is contraindicated in HCC with portal vein thrombosis (PVT), and no systemic therapy has improved survival in patients with advanced HCC.⁴,⁵ Advanced HCC with PVT has an extremely poor prognosis, with a median survival of only 3 months.⁶-⁸ Various therapeutic methods, including surgical resection of PVT,⁹,¹¹ transcatheter chemoembolization to necrotize PVT,¹²,¹³ and arterial or systemic infusion of chemotherapeutic agents¹⁴,¹⁵ have been used to eliminate PVT. However, the results have been disappointing. Radiation is sometimes effective, but the indication is often limited by the extent of the lesion or impaired liver function.¹⁶

Sorafenib is an oral multikinase inhibitor with antiangiogenic and antiproliferative effects. In the multicenter, double-blind, randomized, phase III study, the median survival and time to radiologic progression were nearly 3 months longer for advanced HCC patients treated with sorafenib than for those given placebo.¹⁷ Sorafenib is the only systemic treatment shown to be effective against advanced HCC, and combining other anticancer treatment modalities with sorafenib is strongly suggested. Recently sorafenib combined with TACE¹⁸ and
sorafenib combined with radiation\(^1\) have been reported. Here, we report a case of successful treatment combining sorafenib with hepatic arterial infusion chemotherapy (HAIC) of PVT in advanced HCC.

Fig. 1. Liver dynamic computed tomography images obtained before and after treatment. (A-C) Before treatment. (A) An arterial phase, 8.5×7.5-cm-sized, well-enhanced mass is noted in the hepatic dome. (B) Portal phase, showing mass washout. (C) Portal phase, with the right main portal vein appearing enlarged with massive portal vein thrombosis (arrows). (D-F) Two months after sorafenib monotherapy. (D) Arterial phase, showing that arterial enhancement in the hepatic mass is markedly decreased. (E) Portal phase, showing continued presence of the hypoattenuated mass. (F) Portal phase, showing revascularization of the portal vein thrombosis (arrows). (G-I) Eight months after sorafenib treatment combined with hepatic arterial infusion chemotherapy and transcatheter arterial chemoembolization. (G) Arterial phase, showing no definite arterial enhancement with a tiny amount of lipiodol uptake (arrows). (H) Portal phase, showing a smaller hypoattenuated mass. (I) Portal phase, showing revascularization of the portal vein thrombosis (arrows).
CASE REPORT

A 50-year-old man affected by hepatitis B virus (HBV)-related cirrhosis was hospitalized with abdominal distension due to ascites, in May 2008. He had been diagnosed with liver cirrhosis 5 years previously, but had not been followed up. Upon admission, shifting dullness and pretibial pitting edema were observed. Initial laboratory investigations were as follows: white blood cell count 6,900/mm³, hemoglobin 13.3 g/dL, hematocrit 39.7%, platelets 136,000/mm³, prothrombin time 66.9% (international normalized ratio, 1.41), aspartate aminotransferase 124 IU/L, alanine aminotransferase 122 IU/L, albumin 2.5 g/dL, total bilirubin 1.1 mg/dL, alpha-fetoprotein (AFP) 214.68 ng/mL. Hepatitis B surface antigen was positive and antibody was negative, and hepatitis B e antigen and antibody were negative, and HBV DNA was 2.99×10⁶ copies/mL. The initial liver dynamic computed tomography (CT) revealed an 8.5×7.5-cm sized enhancing mass in the right lobe and multiple daughter nodules in the left lobe, with massive thrombosis in the right portal vein that extended to the main portal vein (Fig. 1). The common hepatic artery and para-aortic lymph nodes were also noted. Chest enhancing CT showed metastatic intrathoracic lymphadenopathy. The clinical stage was stage IV, based on UICC TNM classification (6th edition). Performance status was Eastern Cooperative Oncology Group (ECOG) 1 and Child-Pugh score was B8 and MELD was 7.

For this case of advanced HCC with PVT and extrahepatic metastasis, we considered systemic chemotherapy and prescribed sorafenib (Nexavar®; 400 mg b.i.d). He also received lamivudine 100 mg/day for HBV-related cirrhosis. After 2 months, the longest diameter of the main tumor had decreased from 8.5 cm to 6.3 cm, and the right main PVT was considerably diminished (Fig. 1). However, no additional response was seen during the subsequent 2 months of sorafenib monotherapy. After 4 months of the initial treatment, tumor response was stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (RECIST). To achieve better tumor response, we combined HAIC with sorafenib.

Daily cisplatin (7 mg/m² on Days 1-5) and 5-fluorouracil (170 mg/m² on Days 1-5) were infused repeatedly ev-
Fig. 2. Treatment course of sorafenib and combined treatment. HBV, hepatitis B virus; AFP, α-Fetoprotein; HAIC, hepatic arterial infusion chemotherapy; TACE, transarterial chemoembolization.

**DISCUSSION**

This patient experienced a significant regression of advanced HCC with PVT after sorafenib treatment combined with HAIC. Moreover, PVT revascularization was achieved after sorafenib monotherapy and following HAIC, making the TACE approach possible. This case is the first report of a partial response and PVT revascularization after sorafenib therapy combined with HAIC and TACE.

Although sorafenib is the only proven systemic chemotherapy for HCC, the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) trial resulted in no complete responses and a partial response rate of only 2%. However, 71% of the patients exhibited stable disease, and patients who had received sorafenib treatment had a median survival benefit, of nearly a 3-months compared with those who had received placebo. Thus, sorafenib combined with other antitumor treatment strategies has been strongly required to increase tumor response and survival rate.

In the case, we are reporting, three important points stand out. First, a 2-month course of sorafenib monotherapy resulted in considerable PVT revascularization. Novi et al. have reported HCC improvement and PVT revascularization after 15 weeks of sorafenib monotherapy. For the mechanism for the PVT revascularization of sorafenib, Li et al. have suggested that vascular endothelial growth factor may play a pivotal role both in HCC angiogenesis and in PVT onset and evolution, so sorafenib could exert a beneficial effect on PVT by the inhibition of the vascular endothelial growth factor receptor pathway. Second, sorafenib combined with HAIC and TACE subsequent to sorafenib monotherapy, resulted in further tumor response. We suppose that the antitumor effects of HAIC and TACE added to the effect of targeted sorafenib therapy and doubled the tumor response. Third, the toxicity of combined treatment is a substantial problem. During sorafenib treatment combined with HAIC, we modified the sorafenib dose to reduce toxicity and side effects. In the first combined session, sorafenib was stopped 5 days prior to beginning HAIC. After HAIC, sorafenib was resumed at half-dose (200 mg b.i.d.). In the second session, the patient tolerated a half-dose of sorafenib throughout the course of combined treatment. However, during the third session, the patient showed general weakness on third day of HAIC combined with a half-dose of sorafenib. The sorafenib was stopped, and the half-dose was resumed 1 week after treatment. In the fourth session, sorafenib was stopped for a period of 1
combined treatment is warranted. Caution should be observed in combining sorafenib with HAIC because of the toxicity, and the dosage and period of combined treatment should be modified as necessary. Careful patient selection is also essential.

In this case, we stopped sorafenib after HCC aggravation. Although sorafenib resistance has not been elucidated yet, sorafenib resistance and sorafenib chemosensitivity before treatment are most important factors and have to be investigated in sorafenib therapy.

In conclusion, sorafenib combined with intra-arterial chemoinfusion and TACE showed significant tumor re-
gression and PVT-revascularization. Further randomized and controlled study to identify the efficacy and safety of combined treatment is warranted.

REFERENCES